Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0079

Scientific exchange · Dr. Daniel Weber

23 Feb 2026 · Virtual · Dr. Daniel Weber, Johns Hopkins · MSL James Whitfield · Vantrexa

ReviewedManualENG-0079—

Capture insight from this engagement

Location: Johns Hopkins
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients

Scientific content used

irAE management guide

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with thoracic medical oncologist at Johns Hopkins. Discussed elderly / ecog 2 patients.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0079

Audit history (0)

All create, update and approval events for this record

No audit events in sample data